Covista Inc. (CVSA) Stock Price & Analysis
Covista Inc. (CVSA) fell 0.20% to USD 126.08 as of June 10, 2026 at 00:51 UTC, according to Nexqual real-time market data.
CVSA last closed at USD 126.33; the session ranged USD 124.59–127 on volume of 126,875 shares. Market capitalization is $4.29B, with a 52-week range of USD 86.97–156.26 (NYQ). Source: Nexqual, June 10, 2026 at 00:51 UTC.
Key Statistics (as of June 10, 2026 at 00:51 UTC)
| Price | USD 126.08 |
|---|---|
| Change | ▼ 0.20% (down) |
| Previous Close | USD 126.33 |
| Open | USD 126.4 |
| Day Range | USD 124.59 – 127 |
| 52-Week Range | USD 86.97 – 156.26 |
| Volume | 126,875 shares |
| Market Cap | $4.29B |
| Exchange | NYQ |
Technical Analysis (CVSA)
Nexqual's technical model rates CVSA "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 00:51 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.06 (neutral) |
| vs SMA50 | Above (USD 119.5) |
| MACD | 1.61 (positive) |
Analyst Ratings (CVSA)
Wall Street analysts rate CVSA "Strong Buy" based on 4 analysts, with a mean price target of USD 156.25 (range USD 140–175), per Nexqual as of June 10, 2026 at 00:51 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 156.25 |
| High Target | USD 175 |
| Low Target | USD 140 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (CVSA)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 1.89 |
| Revenue Estimate | $486.55M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.98 vs est 1.72 ▲ beat |
| 2025-12-31 | USD 2.43 vs est 2.19 ▲ beat |
| 2025-09-30 | USD 1.75 vs est 1.58 ▲ beat |
| 2025-06-30 | USD 1.66 vs est 1.53 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
Financials & Fundamentals (CVSA)
| Total Revenue | $1.91B |
|---|---|
| Revenue Growth (YoY) | +4.50% |
| Gross Margin | +57.28% |
| Operating Margin | +18.93% |
| Profit Margin | +12.26% |
| ROE | +17.85% |
| Debt / Equity | 53.98 |
| Current Ratio | 0.7 |
| Total Cash | $146.98M |
| Total Debt | $736.29M |
| Free Cash Flow | $274.83M |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
Financial Health Score (CVSA)
Nexqual rates Covista Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 00:51 UTC.
| Growth | Solid — Revenue +13% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 57%, operating 19% |
| Balance Sheet | Mixed — $147M cash vs $736M debt |
| Cash Flow | Strong — FCF $275M, 15% margin |
| Efficiency | Solid — ROE 18%, ROA 8.4% |
Ownership (CVSA)
| Insider Ownership | +2.59% |
|---|---|
| Institutional Ownership | +103.86% |
| Shares Outstanding | 34.03M |
| Float | 33.18M |
| Short % of Float | +6.50% |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
Leadership (CVSA)
Covista Inc. is led by Stephen W. Beard (age 54), CEO & Chairman, per Nexqual as of June 10, 2026 at 00:51 UTC.
| CEO & Chairman | Stephen W. Beard (age 54) |
|---|---|
| Senior VP & CFO | Robert J. Phelan (age 59) |
| Chief Growth & Innovation Officer and President of Walden University | Michael Betz (age 51) |
| President of Adtalem Medical & Veterinary | Scott Day Liles (age 58) |
| Vice President of Investor Relations | Jeremy Cohen |
Major Backers & Investors (CVSA)
Notable institutional backers of Covista Inc. include FMR, LLC, Ariel Investments, LLC, Capital Group, according to Nexqual as of June 10, 2026 at 00:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 7.8% |
| Ariel Investments, LLC | 5.68% |
| Capital Group | 3.02% |
| Ariel Investment Trust-Ariel Fund | 2.51% |
| Wellington Management | 2.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.91% |
| Vanguard Group | 19.33% |
| Dimensional Fund Advisors | 5.21% |
| State Street | 3.97% |
| Geode Capital | 2.51% |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
From Covista Inc.'s Latest SEC 10-K Filing (filed 2025-08-07)
Key Strengths & Strategy (as disclosed to the SEC)
- Congress and federal agencies, including ED, the Consumer Financial Protection Bureau ("CFPB"), and the Federal Trade Commission ("FTC"), review the role that proprietary educational institutions play in higher education.
- The 90/10 Rule An ED regulation known as the 90/10 Rule affects only proprietary institutions participating in Title IV programs, including each of Adtalem's institutions.
Partnerships
- The MPAS degree program prepares students for the practice of general medicine as Physician Assistants in collaboration with a licensed physician and healthcare team and is designed to be completed in two years.
- In September 2019, AUC opened its medical education program in the U.K. in partnership with University of Central Lancashire ("UCLAN").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STRA | Strategic Education, Inc. | USD 80.51 | ▼ 1.31% |
| ESI | Element Solutions Inc. | USD 41.28 | ▲ 3.61% |
| CECO | CECO Environmental Corp. | USD 95.45 | ▲ 22.33% |
| COCO | The Vita Coco Company, Inc. | USD 74.22 | ▲ 0.18% |
| LOPE | Grand Canyon Education, Inc. | USD 149.65 | ▼ 1.91% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:51 UTC. This page is informational and not investment advice.